98%
921
2 minutes
20
Background: Curative options for large hepatocellular carcinoma (LHCC) are limited because of the high risk of early and extrahepatic recurrence. However, only a few studies report data on long-term outcomes in large cohorts of resected LHCC. We therefore investigated timing and site of recurrence of LHCC and assessed factors strictly associated with adverse patterns.
Patients And Methods: This was a retrospective, international, multicenter study of patients undergoing anatomic resection of HCC ≥ 5 cm at 12 hepatobiliary high-volume centers. Extrahepatic recurrence was defined as any distant site of metastasis, while recurrence within 2 years after surgery was classified as early recurrence.
Results: A total of 869 patients were included. Recurrence was observed in 487 (56%) cases. Patterns associated with reduced overall survival were early (p < 0.001) and simultaneous intrahepatic and extrahepatic recurrence (p = 0.038). Variables independently associated with early recurrence were age (p = 0.037), major hepatectomy (p = 0.023), microvascular invasion (p = 0.011), satellites nodules (p = 0.005), and open approach (p = 0.025). Variables correlated with simultaneous intra- and extrahepatic relapse were age (p < 0.001), preoperative transarterial chemoembolization (TACE) (p < 0.001), microvascular invasion (p < 0.001), and satellite nodules (p = 0.026).
Conclusions: Surgery for LHCC is associated with a high risk of early recurrence. Apart from pathological variables, factors independently associated with adverse patterns were open approach and age for the early recurrence and preoperative TACE and age for simultaneous intra-extrahepatic relapse. BCLC stage was not associated with timing nor with site of recurrence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1245/s10434-025-17673-3 | DOI Listing |
JMIR Med Inform
September 2025
Department of Hepatobiliary and Vascular Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Background: Primary liver cancer, particularly hepatocellular carcinoma (HCC), poses significant clinical challenges due to late-stage diagnosis, tumor heterogeneity, and rapidly evolving therapeutic strategies. While systematic reviews and meta-analyses are essential for updating clinical guidelines, their labor-intensive nature limits timely evidence synthesis.
Objective: This study proposes an automated literature screening workflow powered by large language models (LLMs) to accelerate evidence synthesis for HCC treatment guidelines.
Adv Sci (Weinh)
September 2025
China-New Zealand Joint Laboratory on Biomedicine and Health, State Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong-Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Resea
TP53 mutations are highly associated with hepatocellular carcinoma (HCC), a common and deadly cancer. However, few primary drivers in the progression of HCC with mutant TP53 have been identified. To uncover tumor suppressors in human HCC, a genome-wide CRISPR/Cas9-based screening of primary human hepatocytes with MYC and TP53 overexpression (MT-PHHs) is performed in xenografts.
View Article and Find Full Text PDFOncol Res
September 2025
Department of Biliary-Pancreatic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, largely driven by an immunosuppressive tumor microenvironment (TME) that facilitates tumor growth, immune escape, and resistance to therapy. Although immunotherapy-particularly immune checkpoint inhibitors (ICIs)-has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses, their clinical benefit as monotherapy remains suboptimal. This limitation is primarily attributed to immunosuppressive components within the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs).
View Article and Find Full Text PDFBiochem Pharmacol
September 2025
Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China. Electronic address:
Metabolic dysfunction-associated steatohepatitis (MASH) affects a large proportion of the global population and is widely regarded as the fastest growing cause of hepatocellular carcinoma. Currently, approved therapeutic strategies for MASH are limited. Therefore, this study used the Connectivity Map (CMap) database to identify a candidate compound for MASH, evaluate its efficacy in experimental models, and explore its mechanism of action.
View Article and Find Full Text PDFJ Inflamm Res
August 2025
Department of Comprehensive Surgery, Wenzhou Central Hospital, Wenzhou, People's Republic of China.
Purpose: Hepatocellular carcinoma (HCC) recurrence remains a significant burden on global healthcare. Hepatic ischemia-reperfusion injury (HIRI) is a common complication in liver surgery and may be a contributing factor to HCC recurrence. Nevertheless, the potential mechanism underlying HIRI-induced HCC recurrence has not been fully elucidated.
View Article and Find Full Text PDF